Introduction {#S1}
============

There are now about 90 defined subtypes of lymphomas, and the clinical outcomes are different for the different subtypes, although many cannot currently be easily distinguished.[@R1] Initially, lymphomas were classified by clinical factors, which allowed clinicians to distinguish those that had a good prognosis from those that had a poor prognosis. More recently, molecular signatures associated with prognosis have been identified.[@R2] For example, the germinal center B-cell-like (GCB) subtype of diffuse large B-cell lymphoma (DLBCL) was found to have a significantly better survival rate than the non-GCB DLBCL. However, such gene profiling is not yet possible as a clinical routine, so the search is ongoing for a clinical surrogate to identify these subtypes.

Improving on the efficacy of CHOP
---------------------------------

The standard regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) given over a 3-weekly cycle (CHOP-21) was easy to use and produced acceptable response rates. However, it did not provide a long-term survival benefit for most patients --only about 40% of patients had long-term disease control.[@R3] Several attempts were therefore made to improve on the efficacy of this regimen, using conventional chemotherapy.

Treatment with doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP)-14, in which the doses of both doxorubicin and cyclophosphamide are higher than in the standard CHOP regimen, was originally devised as a standard treatment for all T-cell lymphomas. In two studies, there was a significant improvement in favor of ACVBP, compared with CHOP-21, in patients who were older and had a poor prognosis,[@R4] and in those who were young and had a good prognosis,[@R5] although ACVBP was more toxic than CHOP. In a third study, ACVBP was shown to be more effective than methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD) in patients with low-risk aggressive lymphoma.[@R6]

Increasing the dose intensity of CHOP by reducing the dose interval from 3 to 2 weeks (CHOP-14) produced a clear increase in efficacy in both young and elderly patients.^[@R7],[@R8]^ Another study investigated the efficacy of ACVBP followed by either sequential high-dose chemotherapy or intensive chemotherapy plus autologous bone marrow transplant, in patients with a high International Prognostic Index (IPI). Bone marrow transplant was associated with 64% overall survival in the long term.[@R9] Thus, this was the level of response and efficacy that could be produced in patients with a poor prognosis, prior to the introduction of rituximab therapy.

Treatment with R-CHOP
---------------------

The first demonstration that rituximab plus CHOP (R-CHOP) was more effective than CHOP alone was obtained after the initial 2 years of the Groupe d\'Étude des Lymphomes de l\'Adulte (GELA) LNH98.5 study.[@R10] Long-term follow-up of this study over 7 years (and now 10 years) has shown that the advantages are maintained, in terms of event-free, progression-free, disease-free, and overall survival.[@R11] This superiority of R-CHOP over CHOP was subsequently confirmed in other studies: the MInT study in young patients with good prognosis,[@R12] the RICOVER study in elderly patients,[@R13] the British Columbia study in patients with advanced disease,[@R14] and the Eastern Cooperative Oncology Group study in elderly patients, which also demonstrated the efficacy of rituximab maintenance therapy.[@R15] The RICOVER study also showed that six cycles of CHOP-14 plus eight infusions of rituximab were as effective as eight cycles of R-CHOP-14.[@R13]

A final research question remained about the relative efficacies of the 2- *versus* 3-week R-CHOP regimens (R-CHOP-14 *versus* R-CHOP-21), as these had not been compared directly. The interim results of the LNH03-6B study have been presented in abstract form,[@R16] and showed no significant difference between the two regimens, and a somewhat higher efficacy and lower toxicity for the less dose-intense R-CHOP-21. A second interim analysis, recently presented at the 11^th^ International Conference on Malignant Lymphoma, confirmed these results.[@R17]

Improving on the efficacy of R-CHOP
-----------------------------------

The efficacies of R-ACVBP and R-CHOP were compared in the LNH03-2B study (clinicaltrials.gov identifier NCT00140595), which involved young patients with DLBCL and an age-adjusted IPI of 1. An interim analysis showed superiority of R-ACVBP-14 over R-CHOP-21 in terms of 2-year event-free survival. The final analysis, recently presented at the 52^nd^ American Society of Hematology Annual Meeting in December 2010, confirmed a significant advantage for R-ACVBP at 3 years in terms of event-free, progression-free, disease-free, and overall survival.[@R18]

There is little evidence for how best to treat patients with 2--3 adverse prognostic factors, although historically outcomes have been poor. A retrospective analysis of patients with DLBCL treated with R-CHOP showed that response rates were good for patients with 0--2 adverse prognostic factors, but 4-year progression-free survival and overall survival rates were only just over 50% for patients with more than two adverse prognostic factors.[@R19] A group of these hard-to-treat patients (with IPIs of 2--3) were given four cycles of R-ACVBP, followed by carmustine, etoposide, cytarabine, and melphalan (BEAM) and autologous stem-cell transplantation.[@R20] After 4 years of follow-up, progression-free survival was high at 76% ([Figure 1](#F1){ref-type="fig"}), and there was no difference in outcomes between groups of patients with two or three adverse prognostic factors.[@R20] In order to compare ACVBP regimens with and without rituximab, a matched control study was conducted between two trials (LNH98-3B and LNH03-3B), which showed a large difference in favor of the rituximab-containing regimen.[@R20] The results indicate that treatment efficacy can be improved for these patients with IPIs of 2--3, and that an intensive treatment regimen may provide them with a probability of about 75% of living without relapse.

Figure 1Progression-free survival (PFS) in 208 hard-to-treat patients (with an International Prognostic Index of 2--3) with diffuse large B-cell lymphoma, who were given four cycles of rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP), followed by carmustine, etoposide, cytarabine, and melphalan (BEAM) and autologous stem-cell transplantation (*unpublished data*). Intention-to-treat population.

Adapting treatment to individual patient risk
---------------------------------------------

An initial study of the use of \[18F\]fluoro-2-deoxy-D-glucose positron emission tomography (PET) before treatment, after two cycles, and after four cycles showed that it was possible to identify those patients who were PET-negative early in treatment, and thereby to predict with a high degree of accuracy those who would remain disease-free ([Figure 2](#F2){ref-type="fig"}).[@R21] Further studies have refined these assessment methods, to reduce the incidence of false-positives and help develop standardized techniques and criteria that can be widely used.[@R22] Based on these initial results, a Phase II study (LNH2007-3B) has been started to follow PET changes under two treatment regimens, namely R-CHOP-14 and R-ACVBP-14, in patients with DLBCL and an age-adjusted IPI of 2--3.[@R23] PET scans will be performed at baseline, and after two and four cycles, and treatment adapted after cycle 4 depending on the PET results.

Figure 2Examples of sequential \[18F\]fluoro-2-deoxy-D-glucose positron emission tomography (PET) findings in two patients.[@R21] Panels A--C show scans from a patient with truly negative *early PET*, predicting complete response. Panels D--F show scans from a patient with truly positive *early PET*, predicting relapse. Arrows show hilar foci after two (panel E) and four (panel F) cycles of chemotherapy. The Kaplan-Meier plot shows 2-year estimates of event-free survival (EFS) according to *early PET* status after two cycles of chemotherapy.[@R21] From Haioun C *et al.*\[18F\]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376-81. Reprinted with permission from the American Society of Hematology via the Copyright Clearance Center and the authors.

Treatment of follicular lymphoma
--------------------------------

Follicular lymphoma usually grows and spreads slowly, and has few symptoms. The current goal of therapy is to maintain the best quality of life for patients and to treat them only when they develop symptoms. Any therapeutic approach should demonstrate an improvement in patient survival but, because median survival is 14--15 years, surrogate markers such as progression-free survival are needed to assess possible survival benefits.

Randomized trials clearly demonstrated that the addition of rituximab to the commonly used chemotherapies increased patient response rates and survival.^[@R24]--[@R27]^ Therefore, these patients should receive rituximab in addition to chemotherapy. Two studies have also investigated the effects of maintenance therapy in patients who responded to initial treatment. One reported the use of yttrium-90-ibritumomab tiuxetan *versus* no further treatment for patients who showed a complete or partial remission, and showed an advantage for maintenance treatment over the watch-and-wait strategy.[@R28] A second study (PRIMA), completed in 2007, included 1193 patients, 74% of whom had received previous R-CHOP and 23% of whom had received previous rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP).[@R27] The results were in favor of rituximab maintenance therapy, compared with observation alone. After a median follow-up of 36 months, progression-free survival was 74.9% among those receiving rituximab *versus* 57.6% in the observation group (P\<0.0001).[@R27]

Conclusions {#S2}
===========

CHOP has long been the standard therapy for lymphoma. Improvements have been made to the efficacy of this regimen by increasing the dosing frequency, increasing the doses (in the ACVBP regimen), and by adding rituximab immunotherapy to either of these regimens. Research is now underway to investigate the place of new therapies such as lenalidomide, new immunotherapies, and high-dose rituximab in improving patients\' overall survival (see Burchardt in this supplement).
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